• Biologics
    • Modalities
      • Mammalian
      • Microbial
      • ADCs / Bioconjugates
      • mRNA / LNP
      • Drug Product
    • Technologies & Products
      • Expression Technologies
      • Discovery Products
      • Bioprocessing Products
    • Discovery and Preclinical
      • Early De-risking & Optimization
      • Cell Line & Strain Development
      • Process Development & Optimization
      • Analytical Development
      • Formulation Development
      • Non-GMP Manufacture
    • Clinical and Commercial
      • Process Development & Optimization
      • Formulation Optimization
      • cGMP Drug Substance Manufacture
      • cGMP Drug Product Manufacture
    Technical Support
    Regulatory Support
    View all locations
    View all Biologics offerings
    Woman and microscope

    Knowledge Center

    View all the latest resources available on site


    Visit our Knowledge Center

  • Small Molecules
    • Services
      • Drug Substance (API)
      • Particle Engineering
      • Drug Product
    • Technologies
      • Highly Potent API (HPAPI)
      • ADCs
      • Spray Dried Dispersions
      • Micronization & Jet Milling
      • Inhaled Delivery (DPI)
    • Solutions
      • Early Phase API
      • Commercial Production API
      • Bioavailability Enhancement
      • Integrated Offerings
    • Knowledge Center
      • Webinars
      • Presentations
      • Publications
      • Meet the Experts
      • View all
    View all Small Molecules offerings
    View all locations
    Clinical drug development & preformulation

    Knowledge Center

    View all the latest resources


    Visit our Knowledge Center

  • Cell & Gene
    • Services
      • Process Development
      • cGMP Manufacturing
      • Regulatory Consulting
      • Bioassay Services
      • Tissue Acquisition
    • Modalities
      • Autologous
      • Allogeneic
      • Viral Vectors
      • iPSCs
      • Exosomes
    • Technologies
      • MODA® Platform
      • Cocoon® Platform
      • Nucleofector® Technology
      • TheraPEAK® Media
      • Endotoxin and Pyrogen Testing
    • Knowledge Center
      • Webinars
      • Articles
      • Whitepapers & Publications
      • eBooks
      • Presentations
      • View all
    View all Cell & Gene offerings
    View all Bioscience Products
    View all locations
  • Capsules & Health Ingredients
    • Health Ingredients
    • Nutraceutical capsules
    • Pharmaceutical capsules
    • Capsule filling equipment
  • Contact
  • Trending Topics
    New Whitepaper: Optimization of mRNA Manufacturing
    Shaped Around You - Committed to your molecule’s IND
    New Whitepaper: Late-Phase Drug Product Development and Launch
Trending Topics
New Whitepaper: Optimization of mRNA Manufacturing
Shaped Around You - Committed to your molecule’s IND
New Whitepaper: Late-Phase Drug Product Development and Launch
Biologics
Biologics
Modalities
  • Mammalian
  • Microbial
  • ADCs / Bioconjugates
  • mRNA / LNP
  • Drug Product
Technologies & Products
  • Expression Technologies
  • Discovery Products
  • Bioprocessing Products
Discovery and Preclinical
  • Early De-risking & Optimization
  • Cell Line & Strain Development
  • Process Development & Optimization
  • Analytical Development
  • Formulation Development
  • Non-GMP Manufacture
Clinical and Commercial
  • Process Development & Optimization
  • Formulation Optimization
  • cGMP Drug Substance Manufacture
  • cGMP Drug Product Manufacture
Back
Small Molecules
Small Molecules
Services
  • Drug Substance (API)
  • Particle Engineering
  • Drug Product
Technologies
  • Highly Potent API (HPAPI)
  • ADCs
  • Spray Dried Dispersions
  • Micronization & Jet Milling
  • Inhaled Delivery (DPI)
Solutions
  • Early Phase API
  • Commercial Production API
  • Bioavailability Enhancement
  • Integrated Offerings
Knowledge Center
  • Webinars
  • Presentations
  • Publications
  • Meet the Experts
  • View all
Back
Cell & Gene
Cell & Gene
Services
  • Process Development
  • cGMP Manufacturing
  • Regulatory Consulting
  • Bioassay Services
  • Tissue Acquisition
Modalities
  • Autologous
  • Allogeneic
  • Viral Vectors
  • iPSCs
  • Exosomes
Technologies
  • MODA® Platform
  • Cocoon® Platform
  • Nucleofector® Technology
  • TheraPEAK® Media
  • Endotoxin and Pyrogen Testing
Knowledge Center
  • Webinars
  • Articles
  • Whitepapers & Publications
  • eBooks
  • Presentations
  • View all
Back
Capsules & Health Ingredients
Capsules & Health Ingredients
Health Ingredients
Nutraceutical capsules
Pharmaceutical capsules
Capsule filling equipment
Back
Contact
Back
  • Home
  • Biologics
  • Expression Technologies
  • bYlok® Bispecific Pairing Technology

bYlok® bispecific pairing technology

Redefine your bispecific antibody design engineering with elegance, simplicity and confidence. Bispecific antibodies generated using Lonza’s bYlok® technology display >95% correct HC-LC pairing* giving you access to a close-to-nature solution for an IgG-like bispecific antibody.
Contact us
Introduction to bYlok

Bispecific antibodies (bsAb) are emerging as an important class of therapeutics. Bispecific antibodies have increased potential for precision targeting and higher potency. Multi antigen binding can help reduce the development of subsequent clinical resistance. Different strategies have been used in the past to create bsAbs. However, key challenges remain with the developability of bispecific antibodies:

  • Highly engineered formats that least resemble native proteins could have a higher risk of unwanted immunogenicity
  • Expression of two different heavy and light chains in a single cell can create misassembled unwanted species. These impurities can be difficult to remove due to their similarity to the correct format.

*Lonza internal data

Helping you redefine your bispecific design engineering

Lonza’s bYlok® platform technology was developed keeping in mind the evolving needs of antibody-drug developers. The simplicity of application is within the design itself. It provides an engineering solution for bispecific antibodies where two different light chains are needed.

By moving the disulphide bridge from constant domains (CH1/CL) to variable domains (VH/VL), the formation of HC-LC heterodimers is favored. The modifications add minimal changes to the molecule’s natural design to minimize unwanted immune responses and support excellent manufacturability.

Download the brochure

Heterogeneous mixture of very similar speciesPatial solution: Knobs-into-Holes Technology bYlok™ TechnologyHighest probability of mispairing eventsSolves heavy chain mispairing. Knobs and holes are positioned in the CH3 region of antibodies in such a way that hinders formation of homodimers.Disulfide Bridge is moved in one of the ‘half mAbs’ from constant domains (CH1/CL) to variable domains (VH/VL).Favours formation of a heterodimer.Can require two separate cell lines (one for each ‘half mAb’); followed by assembly and fther downstream processingOnly one cell line required and simpli-fied downstream processes.Specificity A12.5%Theoretical yield~25%Theoretical yield>95%**Lonza internal dataSpecificity B
Access bYlok® for your bispecific antibody design. A precision pairing technology that links partners to better possibilities

Access to our bYlok® technology is easy. The technology is available via a simple research license to see if it fits your processes.

Contact us to find out more

Related Technologies

GS Xceed® Gene Expression System
Our GS Gene Expression System® is a market-leading CHO based protein expression technology platform....
Learn More
GS piggyBac® Transposon Technology
We provide unique and versatile transposon based cell line engineering technology that combined with...
Learn More
POTELLIGENT® CHOK1SV® Technology
Produce afucosylated antibodies with enhanced ADCC using POTELLIGENT® CHOK1SV® cell line...
Learn More
XS Technologies® | Pichia & E.coli Expression
Our versatile XS Technologies® offer an extensive microbial expression toolbox, including the XS®...
Learn More
Expression Technical Support
Technical support for your development journey, based on over 35 years of expertise in protein...
Learn More
Our locations

Our R&D Centers of Excellence

Explore our locations
Cambridge, United Kingdom
Cambridge, United Kingdom
Visp in the Fall
Visp, Switzerland
Slough exterior
Slough, UK
Haifa, Israel
Haifa, Israel
Explore our locations
Biologics

Knowledge Center

Knowledge Center
Webinar on-demand
Webinar (on-demand)
Bispecific Antibody Development: Upstream Challenges and Strategies
Biological pipelines are evolving from standard antibody formats to next-generation biologics such...
Webinar on-demand
Webinar (on-demand)
Precision Execution of Bispecifics at Scale from Design to Delivery
Heavy-light chain mispairing is one of the major concerns for producing bispecific antibodies....
KC Whitepaper thumbnail
Whitepaper/Executive Summary
Can Yeast be the Future of Large Scale
Vaccines have been developed at record breaking speeds to fight the COVID-19 pandemic and are...
Knowledge Center
Ways to Contact
  • Contact Us
  • Regulatory Support
  • Locations
  • Partnering with Us
Resources
  • Knowledge Center
  • Meet the Experts
  • Upcoming Events
Terms & Conditions
  • Terms and Conditions
  • Legal Disclaimer
  • Privacy Policy
  • California CCPA Notice
  • Transparency in Coverage
Lonza.com
  • Company Overview
  • News & Media
  • Investor Relations
  • Sustainability
  • Careers
  • Sitemap
© 2023 Lonza. All rights reserved.